Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy von Desar, I.M.E, van Herpen, C.M.L, van Laarhoven, H.W.M, Barentsz, J.O, Oyen, W.J.G, van der Graaf, W.T.A

Volltext

Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982) von van Herpen, C.M.L, Locati, L.D, Buter, J, Thomas, J, Bogaerts, J, Lacombe, D, de Mulder, P, Awada, A, Licitra, L, Bernier, J, Vermorken, J.B

Volltext

Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review von Uijen, M.J.M., Lassche, G., van Engen-van Grunsven, A.C.H., Tada, Y., Verhaegh, G.W., Schalken, J.A., Driessen, C.M.L., van Herpen, C.M.L.

Volltext

Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma von van Boxtel, W., Locati, L.D., van Engen-van Grunsven, A.C.H., Bergamini, C., Jonker, M.A., Fiets, E., Cavalieri, S., Tooten, S., Bos, E., Quattrone, P., Verhaegh, G.W., Schalken, J.A., Licitra, L., van Herpen, C.M.L.

Volltext

Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-po... von Uijen, M.J.M., Lassche, G., van Engen-van Grunsven, A.C.H., Driessen, C.M.L., van Herpen, C.M.L.

Volltext

Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally adv... von Driessen, C.M.L, de Boer, J.P, Gelderblom, H, Rasch, C.R.N, de Jong, M.A, Verbist, B.M, Melchers, W.J.G, Tesselaar, M.E.T, van der Graaf, W.T.A, Kaanders, J.H.A.M, van Herpen, C.M.L

Volltext

A new, simple and objective prognostic score for phase I cancer patients von Füssenich, L.M, Desar, I.M.E, Peters, M.E.W.J, Teerenstra, S, van der Graaf, W.T.A, Timmer-Bonte, J.N.H, van Herpen, C.M.L

Volltext

Reply letter to: Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participant – Reply to Füssenich et al.: A new, si... von van Herpen, C.M.L, Teerenstra, S, Desar, I.M.E, van der Graaf, W.T.A

Volltext

Cetuximab-induced pneumonitis in head and neck cancer patient von De Vos, F.Y.F.L, Driessen, C.M.L, Jaspers, H.C.J, van Herpen, C.M.L, Simons, B

Volltext

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs von van der Velden, D. L., Hoes, L. R., van der Wijngaart, H., van Berge Henegouwen, J. M., van Werkhoven, E., Roepman, P., Schilsky, R. L., de Leng, W. W. J., Huitema, A. D. R., Nuijen, B., Nederlof, P. M., van Herpen, C. M. L., de Groot, D. J. A., Devriese, L. A., Hoeben, A., de Jonge, M. J. A., Chalabi, M., Smit, E. F., de Langen, A. J., Mehra, N., Labots, M., Kapiteijn, E., Sleijfer, S., Cuppen, E., Verheul, H. M. W., Gelderblom, H., Voest, E. E.

Volltext

Molecular Tumor Boards: current practice and future needs von van der Velden, D.L., van Herpen, C.M.L., van Laarhoven, H.W.M., Smit, E.F., Groen, H.J.M., Willems, S.M., Nederlof, P.M., Langenberg, M.H.G., Cuppen, E., Sleijfer, S., Steeghs, N., Voest, E.E.

Volltext

904P Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC) von Weijers, J.A.M., Verhaegh, G.W., Driessen, C.M.L., Engen-van Grunsven, I.V., Devriese, L.A., Slingerland, M., Hoeben, A., Schalken, J.A., Van Herpen, C.M.L.

Volltext

Whole-body hyperthermia in combination with systemic therapy in advanced solid malignancies von Lassche, G., Crezee, J., Van Herpen, C.M.L.

Volltext

911P Case series of docetaxel, trastuzumab, and pertuzumab (DTP) and subsequent ado-trastuzumab emtansine (T-DM1) for recurrent or metastatic (R/M) HER2-positive salivary duct carc... von Uijen, M., Lassche, G., van Engen-van Grunsven, A., Driessen, C., Van Herpen, C.M.L.

Volltext

Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands von Boon, E., Valstar, M.H., van der Graaf, W.T.A., Bloemena, E., Willems, S.M., Meeuwis, C.A., Slootweg, P.J., Smit, L.A., Merkx, M.A.W., Takes, R.P., Kaanders, J.H.A.M., Groenen, P.J.T.A., Flucke, U.E., van Herpen, C.M.L.

Volltext

SP-0625: Merkel cell carcinoma: an oncologic emergency von Kaanders, J., Zwijnenburg, E.M., Takes, R.P., Weijs, W.L.J., Werner, J.E.M., Van Herpen, C.M.L., Adema, G.J., Lubeek, S.F.K.

Volltext

P109 Participation and outcome of older adults in phase I trials: a single institution experience von Timmer-Bonte, J.N.H, Füssenich, L, Desar, I.M.E, Kremer, I, van der Graaf, W.T.A, van Herpen, C.M.L

Volltext

Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma von Nutting, C.M., van Herpen, C.M.L., Miah, A.B., Bhide, S.A., Machiels, J.-P., Buter, J., Kelly, C., de Raucourt, D., Harrington, K.J.

Volltext

1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP) von Verkerk, K., van der Wel, T., Zeverijn, L.J., Geurts, B.S., Spiekman, I.A.C., de Wit, G.F., Roepman, P., Jansen, A., van der Noort, V., Smit, E.F., Hoeben, A., Hendriks, L., Van Herpen, C.M.L., Piet, B., Herder, G., Hashemi, S.M.S., Gelderblom, H., Verheul, H.M.W., Voest, E.E., De Langen, J.

Volltext

P103 Radiation dermatitis in patients receiving radiotherapy with concurrent cetuximab for treatment of head and neck cancer. A new challenge in nursing care von van Opstal, C, Lintz-Luidens, H, Janssens, G.O.R.J, van Herpen, C.M.L

Volltext